Macquarie Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $11.7K | Buy |
|
|||||
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $44.8M | Buy |
|
|||||
|
2024
Q1 | $45.6M | Buy |
|
|||||
|
2023
Q4 | $46.7M | Sell |
|
|||||
|
2023
Q3 | $51M | Buy |
|
|||||
|
2023
Q2 | $29.1M | Sell |
|
|||||
|
2023
Q1 | $50.4M | Sell |
|
|||||
|
2022
Q4 | $78.7M | Sell |
|
|||||
|
2022
Q3 | $156M | Sell |
|
|||||
|
2022
Q2 | $208M | Sell |
|
|||||
|
2022
Q1 | $310K | Buy |
|
|||||
|
2021
Q4 | $227M | Buy |
|
|||||
|
2021
Q3 | $206M | Sell |
|
|||||
|
2021
Q2 | $225M | Buy |
|
|||||
|
2021
Q1 | $231M | Buy |
|
|||||
|
2020
Q4 | $165M | Buy |
|
|||||
|
2020
Q3 | $147M | Buy |
|
|||||
|
2020
Q2 | $106M | Buy |
|
|||||
|
2020
Q1 | $57.2M | Sell |
|
|||||
|
2019
Q4 | $93.9M | Buy |
|
|||||
|
2019
Q3 | $68.4M | Sell |
|
|||||
|
2019
Q2 | $83.1M | Buy |
|
|||||
|
2019
Q1 | $68.7M | Sell |
|
|||||
|
2018
Q4 | $91.9M | Sell |
|
|||||
|
2018
Q3 | $121M | Buy |
|
|||||
|
2018
Q2 | $74.4M | Buy |
|
|||||
|
2018
Q1 | $48.4M | Buy |
|
|||||
|
2017
Q4 | $57.8M | Buy |
|
|||||
|
2017
Q3 | $43.4M | Buy |
|
|||||
|
2017
Q2 | $52.1M | Buy |
|
|||||
|
2017
Q1 | $49M | Buy |
|
|||||
|
2016
Q4 | $32.5M | Sell |
|
|||||
|
2016
Q3 | $39.3M | Buy |
|
|||||
|
2016
Q2 | $4.43M | Buy |
|
|||||
|
2016
Q1 | $4.21M | Buy |
|
|||||
|
2014
Q3 | – | Sell |
|
|||||
|
2014
Q2 | $1.96M | Buy |
|
|||||
|
2014
Q1 | $1.14M | Sell |
|
|||||
|
2013
Q4 | $1.44M | Buy |
|
|||||
|
2013
Q3 | $1.06M | Buy |
|